Beyond ASOs & siRNA: Advancing Next-Generation Oligonucleotide Modalities for Enhanced Therapeutic Impact
26 Jun 2025
New Modalities
-
Exploring new platforms such as DNAzymes, aptamers, and circular RNAs for enhanced stability and function
-
Innovations in conjugation, lipid nanoparticles (LNPs), and extrahepatic targeting strategies
-
Defining characterization, quality control, and safety evaluation standards for next-gen therapeutics